StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio total assets

Total assets on the balance sheet at the end of each period.

Regenxbio's total assets was $386.62M at Jun 30, 2026. For fiscal 2025 it was $453.03M, down 2.8% from the year before. Over ten years it grew 7.4% a year on average. The highest annual figure on record is $1.11B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$453.03M-2.8%
FY2024Dec 31, 2024$465.99M-18.8%
FY2023Dec 31, 2023$573.97M-31.1%
FY2022Dec 31, 2022$833.27M-25.2%
FY2021Dec 31, 2021$1.11B+57.3%
FY2020Dec 31, 2020$708.16M+42.2%
FY2019Dec 31, 2019$497.91M-8.4%
FY2018Dec 31, 2018$543.81M+173.7%
FY2017Dec 31, 2017$198.68M+15.0%
FY2016Dec 31, 2016$172.73M-22.0%
FY2015Dec 31, 2015$221.38M+6241.4%
FY2014Dec 31, 2014$3.49M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$386.62M-33.5%
Q1 FY2026Mar 31, 2026$341.89M-30.4%
Q4 FY2025Dec 31, 2025$453.03M-2.8%
Q3 FY2025Sep 30, 2025$525.20M+1.2%
Q2 FY2025Jun 30, 2025$581.03M+2.0%
Q1 FY2025Mar 31, 2025$490.93M-22.0%
Q4 FY2024Dec 31, 2024$465.99M-18.8%
Q3 FY2024Sep 30, 2024$519.11M-18.1%
Q2 FY2024Jun 30, 2024$569.38M-16.6%
Q1 FY2024Mar 31, 2024$629.22M-15.9%
Q4 FY2023Dec 31, 2023$573.97M-31.1%
Q3 FY2023Sep 30, 2023$633.79M-28.3%
Q2 FY2023Jun 30, 2023$682.46M-28.4%
Q1 FY2023Mar 31, 2023$747.83M-27.1%
Q4 FY2022Dec 31, 2022$833.27M-25.2%
Q3 FY2022Sep 30, 2022$883.79M+10.4%
Q2 FY2022Jun 30, 2022$953.44M+14.0%
Q1 FY2022Mar 31, 2022$1.03B+16.6%
Q4 FY2021Dec 31, 2021$1.11B+57.3%
Q3 FY2021Sep 30, 2021$800.40M+47.9%
Q2 FY2021Jun 30, 2021$836.40M+86.0%
Q1 FY2021Mar 31, 2021$879.44M+89.6%
Q4 FY2020Dec 31, 2020$708.16M+42.2%
Q3 FY2020Sep 30, 2020$541.17M+6.3%
Q2 FY2020Jun 30, 2020$449.74M-15.0%
Q1 FY2020Mar 31, 2020$463.94M-10.6%
Q4 FY2019Dec 31, 2019$497.91M-8.4%
Q3 FY2019Sep 30, 2019$509.24M-1.1%
Q2 FY2019Jun 30, 2019$529.14M+57.5%
Q1 FY2019Mar 31, 2019$519.03M+63.6%
Q4 FY2018Dec 31, 2018$543.81M+173.7%
Q3 FY2018Sep 30, 2018$514.98M+146.1%
Q2 FY2018Jun 30, 2018$335.99M+49.7%
Q1 FY2018Mar 31, 2018$317.22M+41.5%
Q4 FY2017Dec 31, 2017$198.68M+15.0%
Q3 FY2017Sep 30, 2017$209.26M+6.8%
Q2 FY2017Jun 30, 2017$224.38M–
Q1 FY2017Mar 31, 2017$224.13M–
Q4 FY2016Dec 31, 2016$172.73M–
Q3 FY2016Sep 30, 2016$195.98M–

More Regenxbio figures

See a number that looks wrong?